CA1153383A - Dibenzoxepin derivatives and process for the preparation thereof - Google Patents
Dibenzoxepin derivatives and process for the preparation thereofInfo
- Publication number
- CA1153383A CA1153383A CA000205427A CA205427A CA1153383A CA 1153383 A CA1153383 A CA 1153383A CA 000205427 A CA000205427 A CA 000205427A CA 205427 A CA205427 A CA 205427A CA 1153383 A CA1153383 A CA 1153383A
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- formula
- oxepin
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 89
- 230000008569 process Effects 0.000 title claims description 56
- 238000002360 preparation method Methods 0.000 title claims description 9
- APMCUORPNXHBQK-UHFFFAOYSA-N benzo[c][1]benzoxepine Chemical class O1C=C2C=CC=CC2=CC2=CC=CC=C12 APMCUORPNXHBQK-UHFFFAOYSA-N 0.000 title abstract description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 24
- 125000005843 halogen group Chemical group 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 12
- 125000004849 alkoxymethyl group Chemical group 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
- 239000000126 substance Substances 0.000 claims description 20
- 230000001590 oxidative effect Effects 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- BUQVRUQZFSMMIL-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzoxepin-2-yl)propanoic acid Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(C(C(O)=O)C)=CC=C21 BUQVRUQZFSMMIL-UHFFFAOYSA-N 0.000 claims description 9
- ZLHKCAHRTBIOOR-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzoxepin-3-yl)propanoic acid Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC=C(C(C(O)=O)C)C=C12 ZLHKCAHRTBIOOR-UHFFFAOYSA-N 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- OKNAWFBIOJJTDV-UHFFFAOYSA-N 2-(oxepin-2-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC=CO1 OKNAWFBIOJJTDV-UHFFFAOYSA-N 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- PYIHCGFQQSKYBO-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzoxepin-3-yl)acetic acid Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 PYIHCGFQQSKYBO-UHFFFAOYSA-N 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 230000000911 decarboxylating effect Effects 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- YPVCEFZRTOSUSF-UHFFFAOYSA-N 2-(8-chloro-11-oxo-6h-benzo[c][1]benzoxepin-2-yl)propanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C(=O)C2=CC(C(C(O)=O)C)=CC=C21 YPVCEFZRTOSUSF-UHFFFAOYSA-N 0.000 claims description 3
- BCYWXPITXHFIQM-UHFFFAOYSA-N 2-[[4-(carboxymethyl)phenoxy]methyl]benzoic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OCC1=CC=CC=C1C(O)=O BCYWXPITXHFIQM-UHFFFAOYSA-N 0.000 claims description 2
- MHJHFQUUNRQERU-UHFFFAOYSA-N 2-(8-chloro-11-oxo-6h-benzo[c][1]benzoxepin-3-yl)propanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C(=O)C2=CC=C(C(C(O)=O)C)C=C12 MHJHFQUUNRQERU-UHFFFAOYSA-N 0.000 claims 2
- LWQOEVAMZQKLHW-UHFFFAOYSA-N 2-(8-fluoro-11-oxo-6h-benzo[c][1]benzoxepin-3-yl)acetic acid Chemical compound O1CC2=CC(F)=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 LWQOEVAMZQKLHW-UHFFFAOYSA-N 0.000 claims 2
- PYILDHSYWHEEFV-UHFFFAOYSA-N 2-(8-fluoro-11-oxo-6h-benzo[c][1]benzoxepin-3-yl)propanoic acid Chemical compound O1CC2=CC(F)=CC=C2C(=O)C2=CC=C(C(C(O)=O)C)C=C12 PYILDHSYWHEEFV-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- -1 hydroxymethylene group Chemical group 0.000 abstract description 31
- 230000000202 analgesic effect Effects 0.000 abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 8
- 125000005042 acyloxymethyl group Chemical group 0.000 abstract description 6
- 230000003389 potentiating effect Effects 0.000 abstract description 6
- 230000001754 anti-pyretic effect Effects 0.000 abstract description 5
- 239000002221 antipyretic Substances 0.000 abstract description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 125
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 109
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
- 239000000243 solution Substances 0.000 description 64
- 229960001701 chloroform Drugs 0.000 description 63
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 59
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 45
- 239000010410 layer Substances 0.000 description 45
- 238000002844 melting Methods 0.000 description 45
- 230000008018 melting Effects 0.000 description 45
- 239000002904 solvent Substances 0.000 description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 238000000921 elemental analysis Methods 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000001816 cooling Methods 0.000 description 23
- 238000003756 stirring Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 18
- 238000010992 reflux Methods 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 238000004821 distillation Methods 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000011259 mixed solution Substances 0.000 description 13
- 239000006188 syrup Substances 0.000 description 13
- 235000020357 syrup Nutrition 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 229920000388 Polyphosphate Polymers 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 239000001205 polyphosphate Substances 0.000 description 11
- 235000011176 polyphosphates Nutrition 0.000 description 11
- 229940083608 sodium hydroxide Drugs 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000000679 carrageenan Substances 0.000 description 9
- 235000010418 carrageenan Nutrition 0.000 description 9
- 229940113118 carrageenan Drugs 0.000 description 9
- 229920001525 carrageenan Polymers 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960000905 indomethacin Drugs 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 6
- 229960002895 phenylbutazone Drugs 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 5
- 229960000991 ketoprofen Drugs 0.000 description 5
- 229920000137 polyphosphoric acid Polymers 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- MIMZGFBPGISKHQ-UHFFFAOYSA-N 2-(oxepin-3-yl)acetic acid Chemical compound OC(=O)CC1=COC=CC=C1 MIMZGFBPGISKHQ-UHFFFAOYSA-N 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- UCVZPCXWFOJWTC-UHFFFAOYSA-N 2-(1-hydroxypropan-2-yl)-6h-benzo[c][1]benzoxepin-11-one Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(C(CO)C)=CC=C21 UCVZPCXWFOJWTC-UHFFFAOYSA-N 0.000 description 3
- IQHZNYCZSCDXAU-UHFFFAOYSA-N 3-(1-hydroxypropan-2-yl)-6h-benzo[c][1]benzoxepin-11-one Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC=C(C(CO)C)C=C12 IQHZNYCZSCDXAU-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 125000006519 CCH3 Chemical group 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000005147 halomethylbenzenes Chemical class 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- XHRCNWPQPFZGPK-UHFFFAOYSA-N methyl 2-(11-oxo-6h-benzo[c][1]benzoxepin-2-yl)acetate Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)OC)=CC=C21 XHRCNWPQPFZGPK-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 125000005506 phthalide group Chemical group 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000004953 trihalomethyl group Chemical group 0.000 description 3
- AYKYOOPFBCOXSL-UHFFFAOYSA-N (4-hydroxyphenyl)acetonitrile Chemical compound OC1=CC=C(CC#N)C=C1 AYKYOOPFBCOXSL-UHFFFAOYSA-N 0.000 description 2
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XWGFEKBUNZWYGY-UHFFFAOYSA-N 2-(11-hydroxy-6,11-dihydrobenzo[c][1]benzoxepin-2-yl)acetic acid Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(O)C2=CC=CC=C21 XWGFEKBUNZWYGY-UHFFFAOYSA-N 0.000 description 2
- YLKRAIPVHHJEHJ-UHFFFAOYSA-N 2-(6,11-dihydrobenzo[c][1]benzoxepin-2-yl)acetic acid Chemical compound O1CC2=CC=CC=C2CC2=CC(CC(=O)O)=CC=C21 YLKRAIPVHHJEHJ-UHFFFAOYSA-N 0.000 description 2
- UHMDVLKZUPAICQ-UHFFFAOYSA-N 2-[[4-(1-hydroxypropan-2-yl)phenoxy]methyl]benzoic acid Chemical compound C1=CC(C(CO)C)=CC=C1OCC1=CC=CC=C1C(O)=O UHMDVLKZUPAICQ-UHFFFAOYSA-N 0.000 description 2
- KCUWYLSCPKHCJS-UHFFFAOYSA-N 2-acetyl-6H-benzo[c][1]benzoxepin-11-one Chemical compound C(C)(=O)C1=CC2=C(OCC3=C(C2=O)C=CC=C3)C=C1 KCUWYLSCPKHCJS-UHFFFAOYSA-N 0.000 description 2
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- KPKVDZBNVDKRIJ-UHFFFAOYSA-N 4-(1-hydroxypropan-2-yl)phenol Chemical compound OCC(C)C1=CC=C(O)C=C1 KPKVDZBNVDKRIJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 206010017788 Gastric haemorrhage Diseases 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 229940117975 chromium trioxide Drugs 0.000 description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DSGNPWKRHALERN-UHFFFAOYSA-N ethyl 2-(11-oxo-6h-benzo[c][1]benzoxepin-2-yl)acetate Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)OCC)=CC=C21 DSGNPWKRHALERN-UHFFFAOYSA-N 0.000 description 2
- ITCNGBNHRRXPQS-UHFFFAOYSA-N ethyl 2-(11-oxo-6h-benzo[c][1]benzoxepin-3-yl)acetate Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)OCC)C=C12 ITCNGBNHRRXPQS-UHFFFAOYSA-N 0.000 description 2
- 125000004997 halocarbonyl group Chemical group 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- FYWSTUCDSVYLPV-UHFFFAOYSA-N nitrooxythallium Chemical compound [Tl+].[O-][N+]([O-])=O FYWSTUCDSVYLPV-UHFFFAOYSA-N 0.000 description 2
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229940049953 phenylacetate Drugs 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- NVKFUVZIOSOUHB-UHFFFAOYSA-N 1-[[4-(carboxymethyl)phenoxy]methyl]-4-chlorocyclohexa-2,4-diene-1-carboxylic acid Chemical compound ClC1=CCC(COC2=CC=C(C=C2)CC(=O)O)(C=C1)C(=O)O NVKFUVZIOSOUHB-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- BTEWWBNTAGZPIU-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzoxepin-1-yl)acetic acid Chemical compound O1CC2=CC=CC=C2C(=O)C2=C1C=CC=C2CC(=O)O BTEWWBNTAGZPIU-UHFFFAOYSA-N 0.000 description 1
- UHUFXANNLAVUGB-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzoxepin-2-yl)acetamide Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)N)=CC=C21 UHUFXANNLAVUGB-UHFFFAOYSA-N 0.000 description 1
- RABHTPKGIVGGIK-UHFFFAOYSA-N 2-(6,11-dihydrobenzo[c][1]benzoxepin-3-yl)acetic acid Chemical compound C1OC2=CC(CC(=O)O)=CC=C2CC2=CC=CC=C21 RABHTPKGIVGGIK-UHFFFAOYSA-N 0.000 description 1
- RKHJWZBEIQMVGH-UHFFFAOYSA-N 2-(8-chloro-11-oxo-6h-benzo[c][1]benzoxepin-2-yl)acetic acid Chemical compound O1CC2=CC(Cl)=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 RKHJWZBEIQMVGH-UHFFFAOYSA-N 0.000 description 1
- ZSHNOXOGXHXLAV-UHFFFAOYSA-N 2-(chloromethyl)benzonitrile Chemical compound ClCC1=CC=CC=C1C#N ZSHNOXOGXHXLAV-UHFFFAOYSA-N 0.000 description 1
- PRCBMXFQTIYHFC-UHFFFAOYSA-N 2-[[4-(1-acetyloxypropan-2-yl)phenoxy]methyl]benzoic acid Chemical compound C1=CC(C(COC(C)=O)C)=CC=C1OCC1=CC=CC=C1C(O)=O PRCBMXFQTIYHFC-UHFFFAOYSA-N 0.000 description 1
- GYYAJOMOBXMMHA-UHFFFAOYSA-N 2-[[4-(2-ethoxy-2-oxoethyl)phenoxy]methyl]benzoic acid Chemical compound C(=O)(O)C1=C(COC2=CC=C(C=C2)CC(=O)OCC)C=CC=C1 GYYAJOMOBXMMHA-UHFFFAOYSA-N 0.000 description 1
- CFRLKELVBAXCKB-UHFFFAOYSA-N 2-[[4-(2-methoxy-2-oxoethyl)phenoxy]methyl]benzoic acid Chemical compound C1=CC(CC(=O)OC)=CC=C1OCC1=CC=CC=C1C(O)=O CFRLKELVBAXCKB-UHFFFAOYSA-N 0.000 description 1
- ZLNSGZYOFZNWDE-UHFFFAOYSA-N 2-[[4-(carboxymethyl)phenoxy]methyl]-5-chlorobenzoic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OCC1=CC=C(Cl)C=C1C(O)=O ZLNSGZYOFZNWDE-UHFFFAOYSA-N 0.000 description 1
- BLRZICVSJWRTHS-UHFFFAOYSA-N 2-[[4-(cyanomethyl)phenoxy]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1COC1=CC=C(CC#N)C=C1 BLRZICVSJWRTHS-UHFFFAOYSA-N 0.000 description 1
- QKBZVICFFSSIDH-UHFFFAOYSA-N 2-methyl-6h-benzo[c][1]benzoxepin-11-one Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(C)=CC=C21 QKBZVICFFSSIDH-UHFFFAOYSA-N 0.000 description 1
- CRVRSECHLYIUGG-UHFFFAOYSA-N 3-acetyl-6H-benzo[c][1]benzoxepin-11-one Chemical compound C(C)(=O)C=1C=CC2=C(OCC3=C(C2=O)C=CC=C3)C1 CRVRSECHLYIUGG-UHFFFAOYSA-N 0.000 description 1
- ZHMMPVANGNPCBW-UHFFFAOYSA-N 4-Hydroxyhydratropate Chemical compound OC(=O)C(C)C1=CC=C(O)C=C1 ZHMMPVANGNPCBW-UHFFFAOYSA-N 0.000 description 1
- YUSHFLBKQQILNV-UHFFFAOYSA-N 6h-benzo[c][1]benzoxepin-11-one Chemical compound C1OC2=CC=CC=C2C(=O)C2=CC=CC=C21 YUSHFLBKQQILNV-UHFFFAOYSA-N 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000196224 Codium Species 0.000 description 1
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 description 1
- ZTCLCSCHTACERP-AWEZNQCLSA-N N-[(1S)-1-[3-chloro-5-fluoro-2-[[2-methyl-4-(2-methyl-1,2,4-triazol-3-yl)quinolin-8-yl]oxymethyl]phenyl]ethyl]-2-(difluoromethoxy)acetamide Chemical compound C1=C(C=C(C(=C1Cl)COC1=CC=CC2=C(C=3N(N=CN=3)C)C=C(C)N=C12)[C@@H](NC(=O)COC(F)F)C)F ZTCLCSCHTACERP-AWEZNQCLSA-N 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- XGXFBZMLDRHRCT-UHFFFAOYSA-L disodium 2-(4-hydroxyphenyl)acetate Chemical compound OC1=CC=C(C=C1)CC(=O)[O-].[Na+].[Na+].OC1=CC=C(C=C1)CC(=O)[O-] XGXFBZMLDRHRCT-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- QQOVRPBUAUNBAV-UHFFFAOYSA-N ethyl 2-(chloromethyl)benzoate Chemical compound CCOC(=O)C1=CC=CC=C1CCl QQOVRPBUAUNBAV-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MOTRZVVGCFFABN-UHFFFAOYSA-N hexane;2-propan-2-yloxypropane Chemical compound CCCCCC.CC(C)OC(C)C MOTRZVVGCFFABN-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- KMTVZLRMCQLJKN-UHFFFAOYSA-N methyl 2-(11-oxo-6h-benzo[c][1]benzoxepin-3-yl)acetate Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)OC)C=C12 KMTVZLRMCQLJKN-UHFFFAOYSA-N 0.000 description 1
- IRUHXJVPEUBFCZ-UHFFFAOYSA-N methyl 2-[4-[(2-carbonochloridoylphenyl)methoxy]phenyl]acetate Chemical compound ClC(=O)C1=C(COC2=CC=C(C=C2)CC(=O)OC)C=CC=C1 IRUHXJVPEUBFCZ-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- IALPJGLBRDDWNJ-UHFFFAOYSA-N propanoic acid xanthen-9-one Chemical compound CCC(O)=O.C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 IALPJGLBRDDWNJ-UHFFFAOYSA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- UDKYUQZDRMRDOR-UHFFFAOYSA-N tungsten Chemical compound [W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W] UDKYUQZDRMRDOR-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
- C07C37/002—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP83336/1973 | 1973-07-24 | ||
JP8333673A JPS5516428B2 (xx) | 1973-07-24 | 1973-07-24 | |
JP83742/1973 | 1973-07-25 | ||
JP8374273A JPS558979B2 (xx) | 1973-07-25 | 1973-07-25 | |
JP8443473A JPS5516429B2 (xx) | 1973-07-26 | 1973-07-26 | |
JP84434/1973 | 1973-07-26 | ||
JP1692674A JPS5724352B2 (xx) | 1974-02-12 | 1974-02-12 | |
JP1692774A JPS50108281A (xx) | 1974-02-12 | 1974-02-12 | |
JP16926/1974 | 1974-02-12 | ||
JP16927/1974 | 1974-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1153383A true CA1153383A (en) | 1983-09-06 |
Family
ID=27519864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000205427A Expired CA1153383A (en) | 1973-07-24 | 1974-07-23 | Dibenzoxepin derivatives and process for the preparation thereof |
Country Status (11)
Country | Link |
---|---|
AR (1) | AR210725A1 (xx) |
BE (1) | BE818055A (xx) |
CA (1) | CA1153383A (xx) |
CH (6) | CH605896A5 (xx) |
DE (1) | DE2435613B2 (xx) |
DK (1) | DK396874A (xx) |
FR (1) | FR2245356B1 (xx) |
GB (2) | GB1476214A (xx) |
NL (1) | NL159381B (xx) |
SE (2) | SE7409577L (xx) |
YU (5) | YU204274A (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES444144A1 (es) * | 1975-01-14 | 1977-08-16 | Hoechst Ag | Un procedimiento para la preparacion de un acido 6,11-dihi- dro-11-oxo-dibenz (b, e) oxepin-alcanoico. |
DE2600768C2 (de) * | 1975-02-04 | 1983-10-27 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung von 6,11-Dihydro-11-oxodibenz[b,e]-oxepin-alkansäuren |
DE2629569A1 (de) * | 1975-07-30 | 1977-03-31 | Hoechst Ag | 6,11-dihydro-11-oxodibenz eckige klammer auf b,e eckige klammer zu oxepin-alkansaeuren und deren ester sowie verfahren zu ihrer herstellung |
US4082850A (en) | 1976-04-16 | 1978-04-04 | American Hoechst Corporation | Method of treating dermal inflammations |
JPS54122284A (en) * | 1978-02-17 | 1979-09-21 | Dainippon Pharmaceut Co Ltd | Dibenzb,foxepin derivative |
JPS56156273A (en) | 1980-03-31 | 1981-12-02 | Dainippon Pharmaceut Co Ltd | Acetic derivative |
DE3125374A1 (de) * | 1981-06-27 | 1983-01-13 | Hoechst Ag, 6000 Frankfurt | Verfahren zur herstellung von heteroaryl- und dibenzoxepinalkansaeuren |
US4576960A (en) * | 1981-12-23 | 1986-03-18 | Hoechst Roussel Pharmaceuticals Incorporated | 6,11-Dihydro-11-oxo-dibenz[b,e]oxepin derivatives |
US4515946A (en) * | 1981-12-23 | 1985-05-07 | Hoechst-Roussel Pharmaceuticals Inc. | 6,11-Dihydro-11-oxo-dibenz-[b,e]oxepin derivatives |
US4526891A (en) * | 1983-03-10 | 1985-07-02 | Hoechst Roussel Pharmaceuticals Inc. | Substituted alkyl amine derivatives of 6,11-dihydro-11-oxodibenz[b,e]oxepins |
EP0160258B1 (en) * | 1984-04-27 | 1989-09-27 | Hoechst-Roussel Pharmaceuticals Incorporated | (6,11-dihydro-11-oxodibenz(bm,e)oxepinyl)pentanols, a process and intermediates for their preparation and their use as medicaments |
US5008285A (en) * | 1984-04-27 | 1991-04-16 | Hoechst-Roussel Pharmaceuticals, Inc. | (6,11-dihydro-11-oxodibenz[b,e]oxepin-yl)pentanoic acids and derivatives thereof |
US4861887A (en) * | 1988-01-27 | 1989-08-29 | American Cyanamid Company | Herbicidal o-(substituted, aminomethylbenzoic, nicotinic and quinoline-3-carboxylic acids, esters, and salts |
US7687646B2 (en) | 2006-03-28 | 2010-03-30 | Azad Pharmaceutical Ingredients, Ag | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof |
CN106518833A (zh) * | 2015-09-15 | 2017-03-22 | 江苏吉贝尔药业股份有限公司 | 一种新的6,11-二氢-11-氧代二苯并[b,e]噁庚因-2-乙酸制备方法 |
-
1974
- 1974-07-22 YU YU02042/74A patent/YU204274A/xx unknown
- 1974-07-23 CA CA000205427A patent/CA1153383A/en not_active Expired
- 1974-07-23 DK DK396874A patent/DK396874A/da not_active Application Discontinuation
- 1974-07-23 NL NL7409919.A patent/NL159381B/xx not_active IP Right Cessation
- 1974-07-23 FR FR7425559A patent/FR2245356B1/fr not_active Expired
- 1974-07-23 GB GB3258074A patent/GB1476214A/en not_active Expired
- 1974-07-23 SE SE7409577A patent/SE7409577L/xx not_active Application Discontinuation
- 1974-07-23 GB GB4007476A patent/GB1476215A/en not_active Expired
- 1974-07-24 BE BE146913A patent/BE818055A/xx not_active IP Right Cessation
- 1974-07-24 CH CH478877A patent/CH605896A5/xx not_active IP Right Cessation
- 1974-07-24 CH CH479077A patent/CH605898A5/xx not_active IP Right Cessation
- 1974-07-24 CH CH1504677A patent/CH605900A5/xx not_active IP Right Cessation
- 1974-07-24 CH CH478977A patent/CH605897A5/xx not_active IP Right Cessation
- 1974-07-24 AR AR254870A patent/AR210725A1/es active
- 1974-07-24 DE DE2435613A patent/DE2435613B2/de not_active Withdrawn
- 1974-07-24 CH CH1019574A patent/CH594658A5/xx not_active IP Right Cessation
- 1974-07-24 CH CH479177A patent/CH605899A5/xx not_active IP Right Cessation
-
1977
- 1977-05-13 SE SE7705637A patent/SE7705637L/xx not_active Application Discontinuation
-
1981
- 1981-12-25 YU YU03094/81A patent/YU309481A/xx unknown
- 1981-12-25 YU YU03093/81A patent/YU309381A/xx unknown
- 1981-12-25 YU YU03092/81A patent/YU309281A/xx unknown
- 1981-12-25 YU YU03090/81A patent/YU309081A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AR210725A1 (es) | 1977-09-15 |
FR2245356A1 (xx) | 1975-04-25 |
CH605899A5 (xx) | 1978-10-13 |
YU204274A (en) | 1982-06-30 |
DE2435613A1 (de) | 1975-02-27 |
YU309081A (en) | 1983-06-30 |
BE818055A (fr) | 1974-11-18 |
NL159381B (nl) | 1979-02-15 |
CH594658A5 (xx) | 1978-01-13 |
YU309481A (en) | 1983-06-30 |
GB1476214A (en) | 1977-06-10 |
DE2435613B2 (de) | 1979-07-05 |
FR2245356B1 (xx) | 1978-10-13 |
YU309381A (en) | 1983-06-30 |
AU7143174A (en) | 1976-01-22 |
SE7409577L (xx) | 1975-01-27 |
GB1476215A (en) | 1977-06-10 |
NL7409919A (nl) | 1975-01-28 |
CH605897A5 (xx) | 1978-10-13 |
SE7705637L (sv) | 1977-05-13 |
CH605896A5 (xx) | 1978-10-13 |
CH605900A5 (xx) | 1978-10-13 |
DK396874A (xx) | 1975-03-17 |
YU309281A (en) | 1983-06-30 |
CH605898A5 (xx) | 1978-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1153383A (en) | Dibenzoxepin derivatives and process for the preparation thereof | |
Okumura et al. | 4-Oxo-1, 2, 3, 4-tetrahydroquinazolines. I. Syntheses and pharmacological properties of 2-methyl-3-aryl-4-oxo-1, 2, 3, 4-tetrahydroquinazolines and their 1-acyl derivatives | |
CA1153384A (en) | 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives | |
US3984431A (en) | Derivatives of pyrazole-5-acetic acid | |
JPS5811850B2 (ja) | 1− オキソ −2,2− ジチカン −5− インダニロキシ ( マタハチオ # アルカノイツクアシド | |
CA1276938C (en) | Arylacetic acid derivatives | |
FR2647676A1 (fr) | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase | |
US4247706A (en) | Dibenzothiepin derivatives and a process for producing the same | |
US4011328A (en) | Derivatives of pyridine-3-acetic acid, process for their preparation and applications thereof | |
US4057641A (en) | Method of treating inflammation with 2-(2,3-dihydro-2-isopropyl-4-oxo-4H-1-benzopyran-6-yl)propionic acid | |
US3892774A (en) | Cyclo pentathiophene derivatives | |
US4362891A (en) | Alkanoic acid derivatives | |
US3506658A (en) | 2-(10-methyl-2-phenoxazinyl)propionic acid | |
US4116972A (en) | Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation | |
CA1063125A (en) | (1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio)) alkanoic acids and derivatives thereof and processes for preparing same | |
JPH0246035B2 (xx) | ||
US3450698A (en) | Phenthiazine derivatives | |
US3652666A (en) | 2-(3-benzyl-2-methoxy-phenyl) alkanoic acids | |
CA1276158C (en) | 4h-benzo[4,5]cyclohepta[1,2-b]thiophene derivatives | |
Bailey et al. | 282. Synthetical experiments in the chelidonine–sanguinarine group of the alkaloids. Part II | |
Clark et al. | The preparation of some thiochroman-3-ones and derivatives | |
CH392483A (fr) | Procédé de préparation de nouveaux esters d'acides 4-halo-3-sulfamoyl-benzoïques | |
US4013692A (en) | Certain 3-phenyl-benzofuran lower alkanoic acids and esters thereof | |
US4060550A (en) | Novel n'-acylated phenyl-hydrazine and -hydrazone derivatives | |
CA1197511A (fr) | Haloalkyl-8-4h-¬1|-benzopyran-4-ones, et procede de preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |